A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| B-HT 933 dihydrochloride | B-HT 933 dihydrochloride. Group: Biochemicals. Grades: Purified. CAS No. 36067-72-8. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| B-HT 933 dihydrochloride | B-HT 933 dihydrochloride is a selective α2-adrenoceptor agonist displaying 300-fold selectivity for the α2-adrenoceptor over the α1-adrenoceptor. B-HT 933 decreases blood pressure and cardiac output in cats, and exhibits antinociceptive activity in mice. Uses: Adrenergic alpha-agonists. Synonyms: B-HT 933 dihydrochloride; B-HT933 dihydrochloride; B-HT-933 dihydrochloride; Azepexole hydrochloride; Azepexole dihydrochloride; 6-Ethyl-5,6,7,8-tetrahydro-4H-oxazolo[4,5-d]azepin-2-amine dihydrochloride. Grade: ≥99% by HPLC. CAS No. 36067-72-8. Molecular formula: C9H15N3O.2HCl. Mole weight: 254.16. |  |
| B-HT 958 dihydrochloride | B-HT 958 dihydrochloride is a dopamine D2 receptor agonist and an α2-adrenoceptor partial agonist. Synonyms: B-HT 958 dihydrochloride; B-HT958 dihydrochloride; B-HT-958 dihydrochloride; 4H-Thiazolo(4,5-d)azepin-2-amine, 5,6,7,8-tetrahydro-6-((4-chlorophenyl)methyl)-, dihydrochloride; 2-Amino-6-(4-chlorobenzyl)-4,5,7,8-tetrahydro-6H-thiazolo(5,4-d)azepine dihydrochloride; 5,6,7,8-Tetrahydro-6-((4-chlorophenyl)methyl)-4H-thiazolo(4,5-d)azepin-2-amine dihydrochloride. Grade: 99%. CAS No. 36085-44-6. Molecular formula: C14H16ClN3S.2HCl. Mole weight: 366.74. | |
| BHT-A1 | BHT-A1 is produced by Streptococcus rattus BHT. It is active against Gram-positive bacterials. | |
| BHT-ALCOHOL | BHT-ALCOHOL. Product ID: ACMA00008969. Alfa Chemistry - ISO 9001:32057 Certified. |  |
| BHT-B | BHT-B is produced by Streptococcus rattus BHT. BHT-B is a non-modified 5195Da peptide with some similarity to the tryptophan-rich Staphylococcus aureus bacteriocin, aureocin A53. | |
| BI-0115 | BI-0115 is a selective inhibitor of LOX-1 (IC50=5.4 μM) that blocks cellular uptake of oxLDL. BI-0115 binding triggers receptor inhibition by formation of dimers of the homodimeric ligand binding domain[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 4929-23-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg. Product ID: HY-23999. |  |
| BI 01383298 | BI01383298 is a potent and selective inhibitor of human SLC13A5 (Na+/citrate co-transporter) with IC50 of 56 nM in HEK cells overexpressing hSLC13A5. BI01383298 is highly selective over other family members and other transporters with >1000-fold selectivity over others. Synonyms: 1-[(3,5-Dichlorophenyl)sulfonyl]-N-[(4-fluorophenyl)methyl]-4-piperidinecarboxamide. Grade: ≥98%. CAS No. 2227549-00-8. Molecular formula: C19H19Cl2FN2O3S. Mole weight: 445.34. | |
| BI 01383298 | BI 01383298, a chemical probe, is a potent inhibitor of the sodium-citrate co-transporter (SLC13A5) that is highly expressed in the liver[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2227549-00-8. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124738. | |
| BI-0474 | BI-0474 is a potent KRAS G12C inhibitor with IC50 value of 7.0 nM. Synonyms: BI 0474; BI0474. CAS No. 2750570-55-7. Molecular formula: C30H37N9O2S. Mole weight: 587.74. | |
| B I09 | B I09 is a cell permeable IRE-1 RNase inhibitor (IC50 = 1.23 μM) that blocks IRE-1/XBP1 pathway. B I09 exhibits an inhibitory effect on growth of human chronic lymphocytic leukemia (CLL) cells in vitro and promotes CLL regression in a mouse model. Uses: Potential treatment of cll. Synonyms: B-I09; B I09; BI09; 7-(1,3-Dioxan-2-yl)-1,2,3,4-tetrahydro-8-hydroxy-5H-[1]benzopyrano[3,4-c]pyridin-5-one. Grade: ≥98% by HPLC. CAS No. 1607803-67-7. Molecular formula: C16H17NO5. Mole weight: 303.31. | |
| BI-10773 (Empagliflozin) | Empagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3. Group: Inhibitors. Alternative Names: BI 10773. CAS No. 864070-44-0. Pack Sizes: 25mg. Product ID: S8022. Formula: C23H27ClO7. Smiles: C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl. Storage Conditions: 2 years -80 in solvent. |  United States; Europe |
| BI-113823 | BI-113823 is an orally active, blood-brain barrier-permeable bradykinin B1 receptor antagonist, with a Ki value of 5.3 nM for human receptors and 13.3 nM for rat receptors. BI-113823 reduces inflammation-induced mechanical hyperalgesia, as well as the mechanical sensitivity of peripheral afferent nerves and spinal nociceptive-specific neurons. BI-113823 alleviates liver fibrosis and portal hypertension, and improves survival in chronic liver disease models. BI-113823 inhibits the activities of monocytes, neutrophils and hepatic stellate cells, as well as the PI3K/Akt signaling pathway. BI-113823 can be used in research related to inflammatory pain, liver fibrosis and portal hypertension[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1119282-90-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-168906. | |
| BI-1347 | BI-1347 is small molecule CDK8 inhibitor with IC50 of 1.1 nM. BI-1347 was shown to enhance NK-cell activity and promote tumor surveillance. Synonyms: BI 1347; BI1347. CAS No. 2163056-91-3. Molecular formula: C22H20N4O. Mole weight: 356.42. | |
| BI-1347 | BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM). BI-1347 shows anti-tumoral activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2163056-91-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-120350. | |
| BI-1408 | BI-1408 is a potent γ-secretase modulator with an IC50 of 0.04 μM for Aβ42. Synonyms: N-[(5R)-1-Ethyl-4,5,6,7-tetrahydro-1H-indazol-5-yl]-8-(4-fluoro-2-methylphenyl)[1,2,4]triazolo[1,5-a]pyridin-2-amine; [1,2,4]Triazolo[1,5-a]pyridin-2-amine, N-[(5R)-1-ethyl-4,5,6,7-tetrahydro-1H-indazol-5-yl]-8-(4-fluoro-2-methylphenyl)-. Grade: ≥90%. CAS No. 2231075-94-6. Molecular formula: C22H23FN6. Mole weight: 390.46. | |
| BI-1622 | BI-1622 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2681392-19-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-150023. | |
| BI-167107 | BI-167107 is a β-arrestin-biased D2R agonist that binds to β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM. Synonyms: BI 167107; BI167107. Grade: 98%. CAS No. 1202235-68-4. Molecular formula: C21H26N2O4. Mole weight: 370.4. | |
| BI-167107 | BI-167107 is a high affinity, full agonist that binds to the β2 adrenergic receptor (β2AR) with a dissociation constant Kd of 84 pM[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1202235-68-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-121251. | |
| BI-187004 | BI-187004 is an 11β-hydroxysteroid dehydrogenase 1 inhibitor. BI187004 had a positive impact on multiple cardiovascular and metabolic risk factors associated with metabolic syndrome, which differentiates it from other classes of type 2 diabetes drugs. Synonyms: BI 187004; VTP-34072; VTP 34072; VTP34072; (4AR,9aS)-1-(1H-benzo[d]imidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1H-indeno[2,1-b]pyridine-6-carbonitrile. CAS No. 1303515-32-3. Molecular formula: C21H18N4O. Mole weight: 342.40. | |
| BI 224436 | BI 224436 is a novel HIV-1 non-catalytic-site integrase inhibitor; has antiviral EC50s of <15 nM against different HIV-1 laboratory strains and cellular cytotoxicity of>90 μM. Synonyms: BI-224436; BI 224436; BI224436. Grade: >98%. CAS No. 1155419-89-8. Molecular formula: C27H26N2O4. Mole weight: 442.51. | |
| BI 224436 | BI 224436 is a novel HIV-1 noncatalytic site integrase inhibitor with EC50 values of less than 15 nM against different HIV-1 laboratory strains. Uses: Scientific research. Category: Signaling pathways. CAS No. 1155419-89-8. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-18595. | |
| BI-2493 | BI-2493 is a potent pan-KRAS inhibitor that has the potential for the treatment of cancer. Synonyms: BI 2493; BI2493. CAS No. 2937344-16-4. Molecular formula: C24H27N7OS. Mole weight: 461.58. | |
| BI-2493 | BI-2493 is a structural analogue of BI-2865 and a highly selective and orally active pan-KRAS inhibitor. BI-2493 can attenuate tumor growth. BI-2493 can be used for cancer iseases research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2937344-16-4. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153723. | |
| BI 2536 | BI-2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. BI-2536 inhibits Bromodomain 4 (BRD4) with Kd of 37 nM and potently suppresses c-Myc expression. BI-2536 induces apoptosis and attenuates autophagy. Phase 2. Group: Inhibitors. CAS No. 755038-02-9. Pack Sizes: 1g. Product ID: S1109. Formula: C28H39N7O3. Smiles: CCC1C(=O)N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C(C=C4)C(=O)NC5CCN(CC5)C)OC)C. Storage Conditions: 2 years -80 in solvent. | United States; Europe |
| BI 2536 | BI 2536 is a dual PLK1 and BRD4 inhibitor with IC50s of 0.83 and 25 nM, respectively[1]. BI-2536 suppresses IFNB (encoding IFN-β) gene transcription[4]. Uses: Scientific research. Category: Signaling pathways. CAS No. 755038-02-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g. Product ID: HY-50698. | |
| BI-2536 | BI-2563 is a small molecule compound with potential antineoplastic activities. BI 2536 binds to and inhibits Polo-like kinase 1 (Plk1), resulting in mitotic arrest, disruption of cytokinesis, and apoptosis in susceptible tumor cell populations. Plk1, a serine/threonine-protein kinase, is a key regulator of multiple processes fundamental to mitosis and cell division. Synonyms: BI2536; BI 2536; (R)-4-((8-cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide. Grade: 98%. CAS No. 755038-02-9. Molecular formula: C28H39N7O3. Mole weight: 521.65. | |
| BI-2545 | BI-2545, a chemical probe, is a potent autotaxin (ATX) inhibitor that significantly reduces LPA, with IC50s of 2.2 nM and 3.4 nM for human ATX and rat ATX, respectively[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2162961-71-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124772. | |
| BI-2852 | BI-2852 is a KRAS inhibitor. It blocks the interaction of GEF, GAP and effectors with KRAS, thereby inhibiting downstream signal transduction and producing anti-proliferative effects in KRAS mutant cells. Synonyms: BI-2852; 2375482-51-0; CHEMBL4750445; (3~{S})-3-[2-[[[1-[(1-methylimidazol-4-yl)methyl]indol-6-yl]methylamino]methyl]-1~{H}-indol-3-yl]-5-oxidanyl-2,3-dihydroisoindol-1-one; (3S)-5-hydroxy-3-[2-[[[1-[(1-methylimidazol-4-yl)methyl]indol-6-yl]methylamino]methyl]-1H-indol-3-yl]-2,3-dihydroisoindol-1-one; F0K; SCHEMBL24414712; BCP31539; EX-A4793; BDBM50549225; s8959; AKOS040732592; BI2852; BI 2852; MS-29593; HY-126247; CS-0100975; A934943; (S)-5-Hydroxy-3-(2-((((1-((1-methyl-1H-imidazol-4-yl)methyl)-1H-indol-6-yl)methyl)amino)methyl)-1H-indol-3-yl)isoindolin-1-one; (S)-5-hydroxy-3-(2-(((1-((1-methyl-1H-imidazol-4-yl)methyl)-1H-indol-6-yl)methylamino)methyl)-1H-indol-3-yl)isoindolin-1-one. Grade: ≥98% by HPLC. CAS No. 2375482-51-0. Molecular formula: C31H28N6O2. Mole weight: 516.6. | |
| BI-2852 | BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells. Uses: Scientific research. Category: Signaling pathways. CAS No. 2375482-51-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126247. | |
| BI-2865 | BI-2865 is a none-covalent pan-KRAS Inhibitor. It inhibits tumor growth in mice bearing KRAS G12C, G12D, G12V. Synonyms: BI 2865; BI2865. CAS No. 2937327-93-8. Molecular formula: C23H27N7O2S. Mole weight: 465.57. | |
| BI-2865 | BI-2865 is a none-covalent pan-KRAS Inhibitor. BI-2865 binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively. BI-2865 inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 cells (mean IC50: roughly 140 nM)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2937327-93-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153724. | |
| BI-3231 | BI 3231, a chemical probe, is a potent and selective hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) inhibitor, with IC50s of 1 and 13 nM for hHSD17B13 and mHSD17B13, respectively. BI 3231 has the potential for the research of nonalcoholic steatohepatitis (NASH) and other liver diseases[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2894848-07-6. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-148814. | |
| BI-3406 | BI-3406 is a potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1). SOS1 is the guanine nucleotide exchange factor (GEF) and activator of RAS, and mutants of RAS are major oncogenes and occur in many human cancers. Inhibition of SOS1 in a mutant KRAS cell line can suppress tumor growth. Synonyms: BI 3406; BI3406. CAS No. 2230836-55-0. Molecular formula: C23H25F3N4O3. Mole weight: 462.5. | |
| BI-3406 | BI-3406 (compound I-6) is an orally active, highly potent and selective inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC50 of 6 nM. BI-3406 potently reduces the formation of GTP-loaded KRAS, and inhibits MAPK pathway signaling. BI-3406 has anticancer activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2230836-55-0. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-125817. | |
| BI-3663 | BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 (HY-124625) linked to Pomalidomide (HY-10984) with a linker[1]. Anti-cancer activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2341740-84-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111546. | |
| BI-3802 | BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2166387-65-9. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108705. | |
| BI-3802 | BI-3802 is a highly potent BCL6 degrader that inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. It induces BCL6 polymerization and degradation via E3 ligase SIAH1, showing antitumor activity. Grade: ≥98% by HPLC. CAS No. 2166387-65-9. Molecular formula: C24H29ClN6O3. Mole weight: 484.98. | |
| BI-3812 | BI-3812 is potent and efficacious BCL6 inhibitor. It inhibits the BTB domain of BCL6 with an IC50 of ≤3 nM. The high potency and good permeability properties of BI-3812 make this molecule a very good cellular probe compound for testing hypotheses around BCL6 biology. The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL). Synonyms: BI-3812; 2166387-64-8; CHEMBL4755229; 1-(5-chloro-4-((8-methoxy-1-methyl-3-(2-(methylamino)-2-oxoethoxy)-2-oxo-1,2-dihydroquinolin-6-yl)amino)pyrimidin-2-yl)-N,N-dimethylpiperidine-4-carboxamide; SCHEMBL20284237; AMY16876; BCP31903; EX-A2841; BDBM50546197; s8735; AKOS040741329; SB40386; BI 3812; BI3812; AC-31571; MS-30157; HY-111381; CS-0040299; A935150; EN300-22885148; Z3417458909; 1-[5-chloro-4-({8-methoxy-1-methyl-3-[(methylcarbamoyl)methoxy]-2-oxo-1,2-dihydroquinolin-6-yl}amino)pyrimidin-2-yl]-N,N-dimethylpiperidine-4-carboxamide; 1-[5-Chloro-4-({8-methoxy-1-methyl-3-[2-(methylamino)-2-oxoethoxy]-2-oxo-1,2-dihydro-6-quinolinyl}amino)-2-pyrimidinyl]-N,N-dimethyl-4-piperidinecarboxamide; 1-[5-chloro-4-[[8-methoxy-1-methyl-3-[2-(methylamino)-2-oxoethoxy]-2-oxoquinolin-6-yl]amino]pyrimidin-2-yl]-N,N-dimethylpiperidine-4-carboxamide. Grade: ≥98%. CAS No. 2166387-64-8. Molecular formula: C26H32ClN7O5. Mole weight: 558.03. | |
| BI-3812 | BI-3812, a chemical probe, is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2166387-64-8. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111381. | |
| BI-4020 | BI-4020 is an orally active EGFR inhibitor. Synonyms: BI 4020; BI4020. CAS No. 2573869-33-5. Molecular formula: C30H38N8O2. Mole weight: 542.68. | |
| BI-4020 | BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC50=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM). BI-4020 also shows activity against EGFR wt (IC50=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2664214-60-0. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-129550. | |
| BI-409306 | BI-409306 is a potent and selective inhibitor of phosphodiesterase 9A (PDE9A). BI-409306 has been researched as a candidate for the treatment of schizophrenia. Uses: Phosphodiesterase inhibitors. Synonyms: BI 409306; BI409306; SUB 166499; Osoresnontrine. CAS No. 1189767-28-9. Molecular formula: C16H17N5O2. Mole weight: 311.34. | |
| BI-4142 | BI-4142 is a potent, highly selective and orally active HER2 inhibitor with an IC50 of 5 nM[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2682003-36-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-150024. | |
| BI-4394 | BI-4394 (MMP13-IN-3), a chemical probe, is a potent, selective, and orally active MMP-13 inhibitor (IC50=1 nM[1]) for the potential treatment of osteoarthritis[2]. BI-4394 is >1000 selective over other MMPs[1]. Uses: Scientific research. Category: Signaling pathways. Alternative Names: MMP13-IN-3. CAS No. 1222173-37-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-124029. | |
| BI-44847 | BI-44847 is a synthetic bio-active chemical had been in phase II clinical trials for the treatment of type 2 diabetes. Uses: Sodium-glucose transporter 2 inhibitors. Synonyms: BI-44847; BI 44847; BI44847; UNII-43WJ33399D; beta-D-Glucopyranoside,4-((2-fluoro-4-methoxyphenyl)methyl)- 5-methyl-1-(1-methylethyl)-1H-pyrazol-3-yl. Grade: ≥98%. CAS No. 421592-30-5. Molecular formula: C21H29FN2O7. Mole weight: 440.46. | |
| BI-4659 | BI-4659 is a TGFβRI and PDGFRα inhibitor with IC50 values of 19 nM and 99 nM, respectively. BI-4659 inhibits the kinase activities of TGFβRI and PDGFRα, blocks the downstream TGFβRI signaling pathway, and reduces the phosphorylation level of Smad2/3 without altering the expression of TGF-β1. BI-4659 is applicable to research related to pulmonary fibrosis, cancer, and renal ischemia-reperfusion injury[1][2]. Uses: Scientific research. Category: Signaling pathways. CAS No. 894784-05-5. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-171878. | |
| BI-4732 | BI-4732 is an orally active, reversible, ATP-competitive EGFR inhibitor with blood-brain barrier penetration. BI-4732 inhibits the kinase activity of EGFR L858R, T790M and C797S with IC50 values of 1 nM while sparing EGFR wild-type. BI-4732 inhibits EGFR and reduces the phosphorylation of AKT, ERK, and S6K. BI-4732 demonstrates excellent intracranial anti-tumor efficacy in YU-1097 xenograft model harboring EGFR_E19del/T790M/C797S. BI-4732 can be used for the study of non-small cell lung cancer (NSCLC)[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2769715-68-4. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-161275. | |
| BI-4834 | BI-4834 is a potent and selective Polo-like kinase 1 (PLK1) inhibitor. Synonyms: BI4834; BI 4834. Grade: >98%. CAS No. 876371-13-0. Molecular formula: C21H42N4O3S3. Mole weight: 593.76. | |
| BI-4916 | BI-4916 is a proagent of BI-4924. BI-4924 is a NADH/NAD+-competitive PHGDH inhibitor. BI-4916 inhibits cancer cell migration. BI-4916 can be used for cancer, inflammation and infection study[1][2][3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2244451-48-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126253. | |
| BI-4924 | BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal, as well as hepatocytic stability. Intracellular trapping of BI-4924 disrupts serine biosynthesis with an IC50 of 2200 nM at 72 h[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2244452-09-1. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-126254. | |
| BI 6015 | BI 6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that suppresses expression of known HNF4α target genes. BI 6015 produces cytotoxicity in a range of tumor cell lines, including human hepatocellular carcinoma. Synonyms: BI6015; BI 6015; BI-6015. 2-Methyl-1-[(2-methyl-5-nitrophenyl)sulfonyl]-1H-benzimidazole. Grade: ≥98% by HPLC. CAS No. 93987-29-2. Molecular formula: C15H13N3O4S. Mole weight: 331.35. | |
| BI 6015 | BI 6015. Group: Biochemicals. Grades: Purified. CAS No. 93987-29-2. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BI-6015 | BI-6015 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BI6015 represses insulin promoter activity through HNF4α antagonism. BI-6015 can be used for the research of cancer and diabetes[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 93987-29-2. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-108469. | |
| BI605906 | BI605906 is a novel pharmacological inhibitors of the IKK family. It inhibits IKKβ with an IC50 value of 380 nM when assayed at 0.1 mM ATP in vitro. It also inhibits TNFα-dependent IκB degradation and expression of pro-inflammatory mediators IL-6, IL-1b, and CXCL1/2. It not only prevents the phosphorylation of physiological substrates, but also prevents the phosphorylation of the serine residues in IKKβ that trigger its activation. Uses: Bi605906 not only prevents the phosphorylation of physiological substrates, but also prevents the phosphorylation of the serine residues in ikkβ that trigger its activation. Synonyms: BI605906; BI-605906; BI 605906; 3-AMino-4-(1,1-difluoropropyl)-6-(4-Methylsulfonylpiperidin-1-yl)thieno[2,3-b]pyridine-2-carboxaMide. Grade: >98 %. CAS No. 960293-88-3. Molecular formula: C17H22F2N4O3S2. Mole weight: 432.51. | |
| BI605906 | BI605906, a chemical probe, is a novel IKKβ inhibitor with an IC50 value of 380 nM when assayed at 0.1 mM ATP. Uses: Scientific research. Category: Signaling pathways. CAS No. 960293-88-3. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13019. | |
| BI 653048 | BI 653048, a chemical probe, is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM[1]. BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms activity and reduces affinity for the hERG ion channel (IC50>30 μM)[2]. BI 653048 (Compound 103) is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus[3]. Uses: Scientific research. Category: Signaling pathways. CAS No. 1198784-72-3. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12946. | |
| BI671800 | BI671800 is a CRTH2 antagonist. It is used to treat patients with asthma. It is associated with a small improvement in FEV1 in symptomatic controller-naïve asthma patients, and in patients on inhaled corticosteroid (ICS) therapy. Uses: Bi671800 is used to treat patients with asthma. Synonyms: AP-761; AP 761; AP761; 5-Pyrimidineacetic acid, 4,6-bis(dimethylamino)-2-[[4-[[4-(trifluoromethyl)benzoyl]amino]phenyl]methyl]-; 2-(4,6-Bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)benzyl)pyrimidin-5-yl)acetic acid; BI-671800; BI 671800; BI671800. Grade: >98%. CAS No. 1093108-50-9. Molecular formula: C25H26F3N5O3. Mole weight: 501.51. | |
| BI-6901 | BI 6901 is a potent, selective CCR10 antagonist (pIC50=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2040401-92-9. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-116835. | |
| BI-6C9 | BI-6C9 ( N-[4-[(4-Aminophenyl)thio]phenyl]-4-[[(4-methoxyphenyl)sulfonyl]amino]-Butanamide) is a tBid inhibitor that possesses antiapoptotic properties. Bid plays an essential role in matrine-induced AIF translocation. BI-6C9 also blocked matrine-induced AIF translocation detected by confocal microscopy. Bid inhibitor BI-6C9 was applied to confirm the essential role of Bid in cell death induced by matrine. Synonyms: N-[4-[(4-aminophenyl)thio]phenyl]-4-[[(4-methoxyphenyl)sulfonyl]amino]-butanamide. Grade: ≥98%. CAS No. 791835-21-7. Molecular formula: C23H25N3O4S2. Mole weight: 471.6. | |
| BI-6C9 | BI-6C9 is a highly specific BH3 interacting domain (Bid) inhibitor, which prevents mitochondrial outer membrane potential (MOMP) and mitochondrial fission, and protects the cells from mitochondrial apoptosis inducing factor (AIF) release and caspase-independent cell death in neurons[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 791835-21-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-103661. | |
| BI-7273 | BI-7273 is a potent BRD9 bromodomain inhibitor (Ki = 15.4 nM; IC50=19 nM). BI-7273 structurally related BRD7 bromodomain (IC50 = 117 nM) without effect against the BRD2 and BRD4 bromodomain or a panel of kinases. BI-7273 has potential for use in treating acute myeloid leukemia according to a study in vitro (EC50 = 1.4 μM). Uses: A potent brd9 bromodomain inhibitor for the treatment of leukemia. Synonyms: 4-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-2-methyl-1,2-dihydro-2,7-naphthyridin-1-one; 4-(4-((Dimethylamino)methyl)-3,5-dimethoxyphenyl)-2-methyl-2,7-naphthyridin-1(2H)-one; 2,7-Naphthyridin-1(2H)-one, 4-[4-[(dimethylamino)methyl]-3,5-dimethoxyphenyl]-2-methyl-; BI7273; BI 7273. Grade: >98%. CAS No. 1883429-21-7. Molecular formula: C20H23N3O3. Mole weight: 353.41. | |
| BI-7273 | BI-7273 is a selective, and cell-permeable BRD9 inhibitor, with an IC50 and a Kd of 19 and 0.75 nM; also shows high effect on BRD7, with an IC50 and a Kd of 117 nM and 0.3 nM. Uses: Scientific research. Category: Signaling pathways. CAS No. 1883429-21-7. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100351. | |
| BI 749327 | BI 749327 is a potent, selective and orally available TRPC6 inhibitor with IC50 of 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6, respectively. Synonyms: (4-(6-Aminopyridazin-3-yl)piperidin-1-yl)(4-(4-(trifluoromethyl)phenoxy)phenyl)methanone. Grade: 99%. CAS No. 2361241-23-6. Molecular formula: C23H21F3N4O2. Mole weight: 442.43. | |
| BI-749327 | BI-749327 is a potent, high selectivity and orally bioavailable TRPC6 antagonist, with IC50s of 13 nM, 19 nM and 15 nM for mouse, human and guinea pig TRPC6, respectively. BI-749327 is 85-fold more selective for mouse TRPC6 than TRPC3 and 42-fold versus TRPC7[1]. Uses: Scientific research. Category: Signaling pathways. CAS No. 2361241-23-6. Pack Sizes: 10 mM * 1 mL in DMSO; 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-111925. | |
| BI 78D3 | BI 78D3. Group: Biochemicals. Grades: Purified. CAS No. 883065-90-5. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| BI 78D3 | BI 78D3 is a competitive c-Jun N-terminal kinase (JNK) inhibitor (IC50 = 280 nM) with > 100 fold selectivity over p38α and no effect on mTOR and PI-3K. BI 78D3 inhibits JNK interacting protein 1 (JIP1) binding to JNK (IC50 = 500 nM) and prevents JNK substrate phosphorylation. It blocks JNK-dependent Con A-induced liver damage and also restores insulin sensitivity in a mouse model of type II diabetes. Synonyms: JNK Inhibitor X; BI-78D3; BI78D3; BI 78D3; 4-(2,3-Dihydro-1,4-benzodioxin-6-yl)-2,4-dihydro-5-[(5-nitro-2-thiazolyl)thio]-3H-1,2,4-triazol-3-one. Grade: ≥99% by HPLC. CAS No. 883065-90-5. Molecular formula: C13H9N5O5S2. Mole weight: 379.37. | |
| BI-78D3 | BI-78D3 functions as a substrate competitive inhibitor of JNK, inhibit the JNK kinase activity (IC50=280 nM). Uses: Scientific research. Category: Signaling pathways. CAS No. 883065-90-5. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-10366. | |
| BI-847325 | BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Synonyms: BI-847325; BI 847325; BI847325. Grade: 98%. CAS No. 1207293-36-4. Molecular formula: C29H28N4O2. Mole weight: 464.56. | |
| BI-847325 | BI-847325 is an ATP competitive dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively. BI-847325 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. Uses: Scientific research. Category: Signaling pathways. CAS No. 1207293-36-4. Pack Sizes: 10 mM * 1 mL in DMSO; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-18955. | |
Our database is helping our users find suppliers everyday.
